# Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT00030368** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** bortezomib
- **DRUG:** paclitaxel
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00030368
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00030368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00030368, "Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00030368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*